Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab

Mavrilimumab (formerly CAM-3001) is a high-affinity, immunoglobulin G4 monoclonal antibody (mAb) against the granulocyte macrophage colony-stimulating factor (GM-CSF) receptor-α chain. Phase I and II trials in patients with rheumatoid arthritis (RA) treated with mavrilimumab have shown encouraging r...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ther Adv Musculoskelet Dis
Asıl Yazarlar: Cook, Andrew D., Hamilton, John A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2018
Konular:
Reviews
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5784476/
https://ncbi.nlm.nih.gov/pubmed/29387176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X17752036
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller